Skip to main content
Labcorp Holdings Inc. (LH)
NYSE: LH · Real-Time Price · USD
227.17
+0.07 (0.03%)
Nov 4, 2024, 4:00 PM EST - Market closed

Labcorp Holdings Revenue by Segment
Period Ending Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018Mar 31, 2018Dec 31, 2017
Diagnostics Revenue
9.91B 9.70B 9.51B 9.41B 9.35B 9.21B 9.13B 9.20B
Diagnostics Revenue Growth
5.91% 5.22% 4.19% 2.27% -1.97% -7.39% -9.25% -11.19%
Drug Development Revenue
2.85B 2.83B 2.82B 3.51B 4.21B 4.89B 5.65B 5.71B
Drug Development Revenue Growth
-32.26% -42.15% -50.00% -38.45% -27.06% -15.94% -3.73% -2.37%

Operating Income by Segment
Period Ending Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018Mar 31, 2018Dec 31, 2017
Diagnostics Operating Income
1.60B 1.60B 1.57B 1.59B 1.62B 1.68B 1.78B 2.03B
Diagnostics Operating Income Growth
-1.48% -4.68% -12.13% -21.44% -32.72% -38.97% -38.42% -36.81%
Drug Development Operating Income
437.20M 425.30M 422.50M 446.50M 546.00M 647.70M 756.40M 801.10M
Drug Development Operating Income Growth
-19.93% -34.34% -44.14% -44.26% -31.60% -20.40% -7.92% -9.68%
General Corporate Expenses Operating Income
-269.00M -273.20M -382.10M -389.00M -406.80M -396.80M -291.70M -277.50M

Operating Expense Breakdown
Period Ending Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018Mar 31, 2018Dec 31, 2017
Selling, General, and Administrative
2.17B 2.12B 2.07B 2.12B 2.12B 2.11B 2.09B 2.00B
Selling, General, and Administrative Growth
2.18% 0.89% -0.65% 6.07% 5.87% 4.58% 5.02% 2.28%
Amortization
245.20M 237.20M 226.50M 235.70M 237.10M 246.60M 261.50M 259.30M
Amortization Growth
3.42% -3.81% -13.38% -9.10% -18.69% -22.60% -24.11% -29.84%
Restructuring and Other
52.90M 42.40M 46.60M 50.20M 43.60M 51.20M 79.80M 83.80M
Restructuring and Other Growth
21.33% -17.19% -41.60% -40.10% -45.43% -28.19% 118.63% 94.43%
Impairments
- - 349.30M 349.00M 285.50M 275.30M 272.50M 271.50M
Impairments Growth
- - 28.18% 28.55% - - 22,608.33% -
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.